[HTML][HTML] Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
H Yokouchi, K Yamazaki, I Kinoshita, J Konishi… - BMC cancer, 2007 - Springer
Background Gefitinib, an oral agent of epidermal growth factor receptor tyrosine kinase
inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several …
inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several …
Prognostic factors in non-small cell lung cancer patients with postoperative recurrence following third-generation chemotherapy
K Yamazaki, K Sugio, T Yamanaka, F Hirai… - Anticancer …, 2010 - ar.iiarjournals.org
Aim: To analyse the prognostic factors for patients with non-small cell lung cancer (NSCLC)
who underwent cytotoxic chemotherapy with third generation agents or epidermal growth …
who underwent cytotoxic chemotherapy with third generation agents or epidermal growth …
Concordance between epidermal growth factor receptor status in primary non-small-cell lung cancer and metastases: a post-mortem study
SB Watzka, I Rauscher-Pötsch, P Nierlich… - European journal of …, 2010 - academic.oup.com
Objectives: Epidermal growth factor receptor (EGFR)-targeted therapies are a valid
therapeutic option for advanced non-small-cell lung cancer (NSCLC), but unequivocally …
therapeutic option for advanced non-small-cell lung cancer (NSCLC), but unequivocally …
[HTML][HTML] Rescue surgery after immunotherapy/Tyrosine kinase inhibitors for initially unresectable lung cancer
D Galetta, F De Marinis, L Spaggiari - Cancers, 2022 - mdpi.com
Simple Summary Locally advanced or metastatic non-small cell lung cancer (NSCLC) has
been considered for a long time as an unresectable disease. Chemotherapy was …
been considered for a long time as an unresectable disease. Chemotherapy was …
Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable Stage III non–small cell lung cancer: a phase I trial
S Rothschild, SE Bucher, J Bernier… - International Journal of …, 2011 - Elsevier
PURPOSE: To establish the feasibility and tolerability of gefitinib (ZD1839, Iressa) with
radiation (RT) or concurrent chemoradiation (CRT) with cisplatin (CDDP) in patients with …
radiation (RT) or concurrent chemoradiation (CRT) with cisplatin (CDDP) in patients with …
[HTML][HTML] Patterns and risks of postoperative recurrence in completely resected EGFR-mutant non-small cell lung cancer: prognostic significance of routine …
J Ni, T Guo, Y Li, X Yang, Y Li, L Zou… - … lung cancer research, 2019 - ncbi.nlm.nih.gov
Background Recent studies indicate that EGFR-mutant non-small cell lung cancer (NSCLC)
is a heterogeneous disease with varying prognosis. In order to design an optimized …
is a heterogeneous disease with varying prognosis. In order to design an optimized …
Prospective study of gefitinib readministration after chemotherapy in patients with advanced non–small-cell lung cancer who previously responded to gefitinib
T Koizumi, T Agatsuma, K Ikegami, T Suzuki… - Clinical lung cancer, 2012 - Elsevier
Introduction Salvage treatment for acquired resistance to epidermal growth factor receptor
tyrosine kinase inhibitor in patients with non–small-cell lung cancer is a matter of clinical …
tyrosine kinase inhibitor in patients with non–small-cell lung cancer is a matter of clinical …
Treatment after the failure of gefitinib in patients with advanced or recurrent non-small cell lung cancer
R Maruyama, H Wataya, T Seto, Y Ichinose - Anticancer research, 2009 - ar.iiarjournals.org
Background: The optimal treatment for patients with progressive non-small cell lung cancer
who initially show a good response to gefitinib is unclear. Patients and Methods: This study …
who initially show a good response to gefitinib is unclear. Patients and Methods: This study …